These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37489294)
41. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer. Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391 [TBL] [Abstract][Full Text] [Related]
42. Spectrum of NSD1 mutations in Sotos and Weaver syndromes. Rio M; Clech L; Amiel J; Faivre L; Lyonnet S; Le Merrer M; Odent S; Lacombe D; Edery P; Brauner R; Raoul O; Gosset P; Prieur M; Vekemans M; Munnich A; Colleaux L; Cormier-Daire V J Med Genet; 2003 Jun; 40(6):436-40. PubMed ID: 12807965 [TBL] [Abstract][Full Text] [Related]
44. Clinical delineation of SETBP1 haploinsufficiency disorder. Jansen NA; Braden RO; Srivastava S; Otness EF; Lesca G; Rossi M; Nizon M; Bernier RA; Quelin C; van Haeringen A; Kleefstra T; Wong MMK; Whalen S; Fisher SE; Morgan AT; van Bon BW Eur J Hum Genet; 2021 Aug; 29(8):1198-1205. PubMed ID: 33867525 [TBL] [Abstract][Full Text] [Related]
45. Putative Roles of SETBP1 Dosage on the SET Oncogene to Affect Brain Development. Antonyan L; Ernst C Front Neurosci; 2022; 16():813430. PubMed ID: 35685777 [TBL] [Abstract][Full Text] [Related]
46. Cell-type-specific gene expression and regulation in the cerebral cortex and kidney of atypical Setbp1 Whitlock JH; Soelter TM; Howton TC; Wilk EJ; Oza VH; Lasseigne BN J Cell Mol Med; 2023 Nov; 27(22):3565-3577. PubMed ID: 37872881 [TBL] [Abstract][Full Text] [Related]
47. SETBP1 is dispensable for normal and malignant hematopoiesis. Tanaka A; Nishimura K; Saika W; Kon A; Koike Y; Tatsumi H; Takeda J; Nomura M; Zang W; Nakayama M; Matsuda M; Yamazaki H; Fukumoto M; Ito H; Hayashi Y; Kitamura T; Kawamoto H; Takaori-Kondo A; Koseki H; Ogawa S; Inoue D Leukemia; 2023 Sep; 37(9):1802-1811. PubMed ID: 37464069 [TBL] [Abstract][Full Text] [Related]
48. Prenatal diagnosis and molecular cytogenetic characterization of an inherited microdeletion of 18q12.3 encompassing SETBP1. Zhou Y; Quan Y; Wu Y; Zhang Y J Int Med Res; 2022 Sep; 50(9):3000605221121955. PubMed ID: 36113068 [TBL] [Abstract][Full Text] [Related]
49. Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. Villani A; Greer MC; Kalish JM; Nakagawara A; Nathanson KL; Pajtler KW; Pfister SM; Walsh MF; Wasserman JD; Zelley K; Kratz CP Clin Cancer Res; 2017 Jun; 23(12):e83-e90. PubMed ID: 28620009 [TBL] [Abstract][Full Text] [Related]
50. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations. Adema V; Larráyoz MJ; Calasanz MJ; Palomo L; Patiño-García A; Agirre X; Hernández-Rivas JM; Lumbreras E; Buño I; Martinez-Laperche C; Mallo M; García O; Álvarez S; Blazquez B; Cervera J; Luño E; Valiente A; Vallespí MT; Arenillas L; Collado R; Pérez-Oteyza J; Solé F Br J Haematol; 2015 Oct; 171(1):137-41. PubMed ID: 25716545 [No Abstract] [Full Text] [Related]
51. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418 [TBL] [Abstract][Full Text] [Related]
52. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422 [No Abstract] [Full Text] [Related]
53. Detection of a novel Yang H; Liu Z; Chen D; Lin W; Wang L; Chen T; Wang R; Yan X Front Pediatr; 2022; 10():920741. PubMed ID: 36147799 [TBL] [Abstract][Full Text] [Related]
58. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750 [TBL] [Abstract][Full Text] [Related]
59. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation. Saika M; Inoue D; Nagase R; Sato N; Tsuchiya A; Yabushita T; Kitamura T; Goyama S Sci Rep; 2018 Oct; 8(1):15873. PubMed ID: 30367089 [TBL] [Abstract][Full Text] [Related]
60. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC. An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]